Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.32 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.32 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.32 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.32 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.32 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.32 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.32 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 2/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7953048 | 0.87 | KDM4E (0.41) | KMT2AATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL7957640 | 0.83 | HDAC4 (0.32) | — | |
| SCHEMBL7954328 | 0.83 | KMT2A (0.40) | KMT2AHSD17B10MAPKAPK2GAAMAPT | |
| SCHEMBL7952493 | 0.81 | GAA (0.37) | KMT2AHSD17B10MAPKAPK2GAAHDAC3 | |
| SCHEMBL7954566 | 0.81 | EGFR (0.33) | MAPK1 | |
| SCHEMBL7952312 | 0.81 | KMT2A (0.40) | KMT2AHSD17B10MAPKAPK2GAAMAPT | |
| SCHEMBL7957230 | 0.80 | KMT2A (0.36) | KMT2AMAPKAPK2GAAMAPTHDAC3 | |
| SCHEMBL7951050 | 0.77 | NAMPT (0.35) | KMT2AHSD17B10GAAHDAC1ROCK2 | |
| SCHEMBL7952179 | 0.75 | SMN1; SMN2 (0.34) | KMT2AGSK3B | |
| SCHEMBL7954372 | 0.74 | ALDH1A1 (0.39) | KMT2AMAPKAPK2GAAHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-30 | — | — | US | disclosed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| EP-3099304-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | Mayo Foundation for Medical Education and Research (US) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015117024-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2015-08-06 | — | — | WO | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101009-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | KMT2A 2918/4885HSD17B10 1185/4885MAPKAPK2 1006/4885 |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | KMT2A 2918/4885HSD17B10 1185/4885MAPKAPK2 1006/4885 |
| US-12209140-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | KMT2A 2918/4885HSD17B10 1185/4885MAPKAPK2 1006/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | KMT2A 3071/4885HSD17B10 1301/4885MAPKAPK2 1209/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | KMT2A 2918/4885HSD17B10 1185/4885MAPKAPK2 1006/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | KMT2A 2918/4885HSD17B10 1185/4885MAPKAPK2 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.